Physician
Ideal Option, PLLC
Ideal Option, PLLC was paid $259.13M by Medicaid between Jan 2018 and Dec 2024, across 72 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 26% of everything it billed.
33Billing provider infoIDEAL OPTION, PLLC
PASCO, WA 99301
PASCO, WA 99301
33aNPI1457788275assigned 10/11/2013
33bProvider typeAddiction Medicine (Preventive Medicine) Physician
28Total paid$259.13M
24GClaims3,887,574
24DCodes billed72
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 549,384 | $29.37M | |
| 2019 | 578,634 | $37.63M | |
| 2020 | 595,910 | $37.35M | |
| 2021 | 594,310 | $40.16M | |
| 2022 | 587,331 | $40.73M | |
| 2023 | 552,761 | $40.34M | |
| 2024incomplete | 429,244 | $33.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 693,731 | 518,693 | $66.36M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 19% | 887,120 | 494,866 | $49.21M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 15% | 280,911 | 178,304 | $38.39M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.7% | 229,541 | 195,753 | $14.85M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 5.2% | 106,876 | 78,454 | $13.36M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 4.9% | 83,252 | 62,796 | $12.63M |
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | 4.8% | 97,349 | 64,900 | $12.34M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 4.3% | 115,729 | 88,172 | $11.12M |
| 82075 | 4.3% | 500,003 | 302,011 | $11.07M | |
| Q3014 | Telehealth originating site facility fee | 3.2% | 356,810 | 295,435 | $8.25M |
| H0001 | Alcohol and/or drug assessment | 2.5% | 12,023 | 11,769 | $6.50M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.9% | 34,464 | 30,048 | $4.96M |
60 more codes
| 99205 | Prolong outpt/office vis | <1% | 12,754 | $2.12M |
| 80361 | <1% | 20,431 | $628K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15,171 | $495K |
| 80346 | <1% | 20,385 | $493K | |
| 80348 | <1% | 20,762 | $489K | |
| 80354 | <1% | 20,475 | $482K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14,062 | $456K |
| 80324 | <1% | 20,400 | $389K | |
| 80362 | <1% | 16,592 | $380K | |
| 80365 | <1% | 16,308 | $376K | |
| 81025 | <1% | 61,102 | $364K | |
| 80358 | <1% | 14,947 | $348K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 10,419 | $338K |
| 80074 | <1% | 7,355 | $280K | |
| 80345 | <1% | 11,397 | $247K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,666 | $184K |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | <1% | 335 | $157K |
| 80353 | <1% | 7,558 | $148K | |
| 80323 | <1% | 14,452 | $145K | |
| 80356 | <1% | 13,873 | $134K | |
| 80355 | <1% | 18,111 | $117K | |
| H2036 | Alcohol and/or other drug treatment program, per diem | <1% | 155 | $116K |
| 80373 | <1% | 14,454 | $108K | |
| 86780 | <1% | 8,899 | $105K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 693 | $95K |
| 86708 | <1% | 7,505 | $83K | |
| 86704 | <1% | 7,411 | $78K | |
| 86706 | <1% | 7,796 | $74K | |
| 80076 | <1% | 9,563 | $66K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,163 | $66K |
| 80368 | <1% | 12,463 | $60K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,512 | $59K |
| 80366 | <1% | 11,537 | $49K | |
| 80369 | <1% | 9,827 | $39K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,236 | $37K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,336 | $34K |
| H0034 | Medication training and support, per 15 minutes | <1% | 983 | $33K |
| 80321 | <1% | 6,919 | $25K | |
| 80305 | <1% | 2,037 | $24K | |
| H2035 | Alcohol and/or other drug treatment program, per hour | <1% | 33 | $23K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,695 | $22K |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 21 | $20K |
| 84439 | <1% | 2,341 | $18K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 309 | $18K |
| 80360 | <1% | 2,032 | $12K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 127 | $11K |
| 80349 | <1% | 946 | $8K | |
| T1016 | Case management, each 15 minutes | <1% | 879 | $7K |
| 80359 | <1% | 382 | $6K | |
| 86803 | <1% | 335 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 75 | $3K |
| 99406 | <1% | 331 | $3K | |
| 80357 | <1% | 387 | $2K | |
| 80372 | <1% | 299 | $2K | |
| 80371 | <1% | 383 | $2K | |
| 80061 | Lipid panel | <1% | 75 | $889.87 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $826.78 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $650.56 |
| 86705 | <1% | 23 | $161.40 | |
| 87340 | <1% | 23 | $141.64 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOWDEN, SHANNON (CRED MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Idea Telemedicine Services LLC | Glasgow, MT | $71K |
| Ideal Telemedicine Services, LLC | Great Falls, MT | $40K |
| Ideal Telemedicine Services, LLC | Helena, MT | $5K |
| Ideal Telemedicine Services LLC | Billings, MT | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.